Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus continue boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate in virologically suppressed HIV-1
2014-003052-31Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darunavir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with confirmed virologic rebound through Week 48. Started Oct 2014; status: completed.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-003052-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003052-31.